Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Goes After Generics In Japan, Forms New Company With Ranbaxy

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - As Teva and Mylan drill deeper into the steadily unfolding Japanese generic drugs market, Daiichi Sankyo - the third largest Japanese drug maker - does not want to be left behind

You may also be interested in...



After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market

MUMBAI - After years of desire to be in the Japanese generics drugs business, Dr. Reddy's Laboratories Ltd. CEO G.V. Prasad reached that milestone in the signing of a memorandum of understanding with Fujifilm Corp. CEO Shigetaka Komori

After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market

MUMBAI - After years of desire to be in the Japanese generics drugs business, Dr. Reddy's Laboratories Ltd. CEO G.V. Prasad reached that milestone in the signing of a memorandum of understanding with Fujifilm Corp. CEO Shigetaka Komori

After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market

Although it surprised many in India to have Fujifilm's name associated with generic drugs, its penchant to explore the Japanese market coincides with the Japanese government's mission to encourage use of generic substitutes in Japan to drive costs down.

Related Content

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel